This symposium review article features evidence, key learnings, and updates presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain. Taking place on 6th September 2022, this article details the key information shared at the symposium, including the spectrum of inflammatory pathways and heterogeneity of chronic obstructive pulmonary disease (COPD), current and emerging phenotypes/endotypes, and unmet needs in the standard-of-care management of patients with COPD.
Latest articlesAll articles
Cutaneous Mucormycosis Co-infection in a Patient with COVID-19
A 54-year-old male tested positive in late February on a screening COVID-19 test performed after a family member’s test had become positive. A few weeks later, they presented to the emergency room at a different hospital centre with shortness of breath and fever.
Current Perspectives and Future Directions of Repeat Pulmonary Rehabilitation Programmes in People with Chronic Obstructive Pulmonary Disease: A Narrative Review of the Literature
The benefits of pulmonary rehabilitation (PR) diminish over 12–24 months following programme completion. A repeat PR programme may potentially prevent or reverse this decline in gains and may provide additional benefits.
Modulating the Expression of Multiple Surface Receptors on Epithelial Cells and Promoting Lung Macrophage Anti-viral Functions by OM-85 Inhibits Severe Acute Respiratory Syndrome Coronavirus 2 Infection
The emergence of a new virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, in December 2019 triggered a global pandemic, forcing much of the world to adopt lockdown strategies and leading to extraordinary threats to the global healthcare system. The clinical manifestations of the disease, referred to as COVID-19, range from mild, self-limiting flu-like respiratory illness to life-threatening multi-organ failure and death.